
Progyny (PGNY) Stock Forecast & Price Target
Progyny (PGNY) Analyst Ratings
Bulls say
Progyny is supported by a differentiated fertility and family-building platform that is winning share, as shown by the record 1.3M new covered lives, near-100% retention, and more than 85 new clients expected to onboard, including large marquee accounts. Its Q3 performance reinforced the thesis that demand remains strong and execution is improving, with revenue of $341.3M, EBITDA of $58.4M, gross margin expansion to 24.5%, and operating cash flow of $57M showing both scale and cash generation. The outlook is further strengthened by an under-penetrated $10B U.S. fertility insurance market, expanding cross-sell opportunities across more than 3M lives, and a balance sheet that supports ongoing share repurchases and disciplined growth.
Bears say
Progyny is facing a tougher fundamental backdrop as elevated attrition, utilization pressure, and an economic downturn could reduce member counts and slow employer adoption of fertility benefits. Its utilization-driven model has already shown quarter-to-quarter volatility, while slower new solution revenue, employment sensitivity, and uncertainty around reproductive rights could further weaken demand and visibility. Competition from traditional carriers and well-funded carve-out rivals, plus pharmacy and physician-network bottlenecks, raises execution risk and supports a more conservative valuation framework tied to moderation in growth.
This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.
Progyny (PGNY) Analyst Forecast & Price Prediction
Start investing in Progyny (PGNY)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Progyny (PGNY) Forecast
Progyny (PGNY) Analyst Forecast & Price Prediction
Start investing in Progyny (PGNY)
Order type
Buy in
Order amount
Est. shares
0 shares